72 patents
Utility
Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
21 Nov 23
The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Dong Hoon Kim, Su Bin Choi, Sol Park, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
Filed: 6 Jul 21
Utility
Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
10 Oct 23
The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof.
Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Su Bin Choi, Sol Park, Dong Hoon Kim, So Young Kim, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha, Eui Chui Lee
Filed: 22 Mar 21
Utility
Process For Preparing Aminopyrimidine Derivatives
5 Oct 23
The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors.
Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
Filed: 2 Jun 23
Utility
Pharmaceutical Compositions Comprising a Diaminopyrimidine Derivative or Pharmaceutically Acceptable Salt Thereof and Processes for Preparing the Same
17 Aug 23
The present invention provides a pharmaceutical composition comprising (S)—N-(1-(2-((4-amino-3-nitrophenyl)amino)-6-propylpyrimidin-4-yl)pyrrolidin-3-yl)acetamide or a pharmaceutically acceptable salt thereof having an activity as a 5-HT4 receptor agonist and an acidifying agent; and a process for preparing the same.
Dong-Min Park, Su-Hyeon Kim, Eun-Pa Cheon, Tae-Lin Ha, Jun-Mo Yang, Yoong-Sik Park
Filed: 1 Jul 21
Utility
3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
1 Aug 23
The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Eui Chul Lee, Sol Park, Hyok Jun Cho, Cheol Hee Lim, So Young Kim, Hyun Ho Choi, Da Na Jeong, Na Yeon Yang, Na Ry Ha
Filed: 6 Jul 21
Utility
Process for preparing aminopyrimidine derivatives
25 Jul 23
The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors.
Sang-Ho Oh, Ja-Heouk Khoo, Jong-Chul Lim, Seong-Ran Lee, Hyun Ju, Woo-Seob Shin, Dae-Gyu Park, Su-Min Park, Yoon-Ah Hwang
Filed: 25 Mar 22
Utility
Method for Producing Dual Function Proteins and Its Derivatives
6 Jul 23
A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein.
Byung Hyun CHOI, In Hwan LIM, Jun Young PARK, Jin Hyoung LEE, Ki Hong KIM, Hae Yong JO, Jun Hwan KIM, Moo Young SONG, Jong Gyun KIM
Filed: 19 Dec 22
Utility
Pyrrolidine and piperidine compounds
23 May 23
The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Tae Han Dong, Yoo Hoi Park, Tae Kyun Kim, Jae Eun Joo, Eun Hye Jung, Jae Won Jeong, Hyun Seung Lee, Do Hoon Kim, Ji Eun Yang, Jun Chui Park, Sang Myoun Lim, Na Ry Ha, Da In Chung, Ji Yeong Gal
Filed: 5 Nov 20
Utility
Processes for preparing a diaminopyrimidine derivative or acid addition salt thereof
11 Apr 23
The present invention provides a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist.
Ja-Heouk Khoo, Doo-Byung Lee, Jun-Sup Lee, Hyun Ju, Woo-Seob Shin
Filed: 26 Jul 22
Utility
5-MEMBERED Heteroaryl-containing Aminopyridine Compounds As Egfr Inhibitors
23 Mar 23
Provided are 5-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
Filed: 26 Aug 22
Utility
Substituted Aminopyridine Compounds As Egfr Inhibitors
23 Mar 23
Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Hyunjoo LEE, Su Bin CHOI, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell Robertson, Jaekyoo LEE, Paresh Devidas SALGAONKAR, Byung-Chul SUH, Jong Sung KOH, So Young HWANG
Filed: 26 Aug 22
Utility
6-MEMBERED Heteroaryl-containing Aminopyridine Compounds As Egfr Inhibitors
23 Mar 23
Provided are 6-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Hyunjoo LEE, Su Bin CHOI, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Jae Young SIM
Filed: 26 Aug 22
Utility
Substituted Aminopyridine Compounds As Egfr Inhibitors
23 Mar 23
Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Byoungmoon LEE, Hyunjoo LEE, Gyu Jin LEE, Su Bin CHOI, Sol PARK, Heejun KIM, Misong KIM, Young Ae YOON, Kwan Hoon HYUN, Tae Kyun KIM, Jae Young SIM, Marian C. BRYAN, Scott KUDUK, James Campbell ROBERTSON
Filed: 26 Aug 22
Utility
3,3-DIFLUOROALLYLAMINES or Salts Thereof and Pharmaceutical Compositions Comprising the Same
9 Feb 23
The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof.
Tae Dong HAN, Hee Jae TAK, Eun Kyung KIM, Eui Chul LEE, Sol PARK, Hyok Jun CHO, Cheol Hee LIM, So Young KIM, Hyun Ho CHOI, Da Na JEONG, Na Yeon YANG, Na Ry HA
Filed: 6 Jul 21
Utility
Salt of an Aminopyridine Derivative Compound, a Crystalline Form Thereof, and a Process for Preparing the Same
26 Jan 23
The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same.
Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
Filed: 17 Mar 22
Utility
Method for producing dual function proteins and its derivatives
24 Jan 23
A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein.
Byung Hyun Choi, In Hwan Lim, Jun Young Park, Jin Hyoung Lee, Ki Hong Kim, Hae Yong Jo, Jun Hwan Kim, Moo Young Song, Jong Gyun Kim
Filed: 20 Apr 18
Utility
Novel Compounds Having Inhibitory Activity Against Glucosylceramide Synthase or Pharmaceutically Acceptable Salt Thereof, Processes for Preparing the Same, and Pharmaceutical Compositions Comprising the Same
5 Jan 23
Provided are a compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON
Filed: 12 Nov 20
Utility
Novel Derivatives Having 2,3-DIHYDRO-1H-INDENE or 2,3-DIHYDROBENZOFURAN Moiety or Pharmaceutically Acceptable Salt Thereof and Pharmaceutical Compositions Comprising the Same
5 Jan 23
Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Ji-Hye KIM
Filed: 12 Nov 20
Utility
Long-acting GDF15 Fusion Protein and Pharmaceutical Composition Comprising Same
5 Jan 23
A fusion protein including a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition containing the same are disclosed.
Seyoung LIM, Young Bong PARK, Sukyung KIM, Bo Ra SIM, Wonee CHONG, Hyun Ho CHOI, Ji Eun YANG, Mi Kyeong JU, Won Tae KIM, Youn Woo LEE, Junhwan KIM
Filed: 25 Nov 20
Utility
Novel Derivatives Having 1,2,3,4-TETRAHYDRONAPHTHALENE Moiety or Pharmaceutically Acceptable Salt Thereof and Pharmaceutical Compositions Comprising the Same
22 Dec 22
Provided are a compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Young-Gyu KONG, Sang-Ho MA, Ick-Hwan SON
Filed: 12 Nov 20